What is Seprafilm?
Seprafilm is a clear piece of thin film that’s used during open abdominal and pelvic surgery to help prevent adhesions, or internal scar tissue. It sticks to your internal tissues and separates them from your organs to help stop them from attaching to one another as they heal.
Seprafilm is made up of 2 types of sugars, one of which occurs naturally in the body. Both of the sugars are safe and are often used in pharmaceuticals, foods, and cosmetics. Once the film is placed inside the body, it turns into a gel and protects against adhesions for 7 days, the time during which adhesions would form.1
How Seprafilm prevents adhesions
| Day 1 |
 |
During surgery, Seprafilm is placed between injured tissues and organs. 1 |
| Day 3 |
 |
Seprafilm separates tissues and organs while the natural healing process takes place.1 |
| Day 5 |
|
While the body heals and creates its own defense against adhesions, Seprafilm continues to act as a barrier.1 |
| Day 7 |
 |
The body has now formed its own cell layer against adhesions. Seprafilm is absorbed and eliminated naturally by the body less than 28 days after application. 1 |
Safe, effective—and used in more than 3 million patients.2
In one study….

Seprafilm is the only adhesion barrier that has been proven safe and effective in both open abdominal and pelvic surgery. Since its introduction more than 14 years ago, Seprafilm has been used in more than 3 million patients. Today, it’s the most widely used adhesion barrier.2 If you’re having open abdominal or pelvic surgery, be sure to ask your doctor about Seprafilm.
Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.
Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.
Please see full prescribing information.
References
-
Seprafilm Adhesion Barrier [package insert]. Cambridge, MA: Genzyme Biosurgery; 2008.
-
Data on file, Genzyme Corp.
-
Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
Seprafilm works
Seprafilm has been shown to reduce adhesions and some of the problems they can cause.
See the studies